Two to three weeks after treatment, the previously paralyzed mice began to walk. Credit: Lehrstuhl für Zellphysiologie
To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again. The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the Journal Nature Communications from 15 January 2021.
When the communication breaks down
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.
Designer protein stimulates regeneration
In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.
Applied in one area, effective in several areas
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements. They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously. “This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Gene therapy
- Gene Therapy for Hemophilia B Shows Promise
A small study finds that an adeno-associated virus gene therapy eliminated both spontaneous bleeding and the need for factor IX prophylaxis in patients with hemophilia B.
- Gene therapy firm fighting blindness expands into new space in RTP
Over the last two years, the Durham company has grown to about 35 full-time employees and could surpass 40 by the end of this year.
- Sarepta to ask FDA for accelerated approval of Duchenne gene therapy
After discussions with the FDA, the biotech aims to submit an application this fall — sooner than expected and ahead of a Phase 3 study that’s now ongoing.
- Sarepta Will Seek Approval of Gene Therapy Before Completing Phase 3 Trial
Sarepta (ticker: SRPT) had said as recently as July 6 that it was in talks with the FDA about submitting the gene therapy, known as SRP-9001, for accelerated approval. Analysts, however, had thought ...
- Heart gene therapy to stop young sudden death risk
Scientists say they should soon be able to effectively cure inherited, life-threatening heart muscle conditions to save more young people from sudden cardiac death. The British Heart Foundation has ...
Go deeper with Google Headlines on:
Gene therapy
Go deeper with Bing News on:
Designer cytokine
- Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
Both studies are scheduled to commence later this year." The presentation, titled "Targeting Biological Synergy At the Receptor Level – Multi-specific Cytokine Inhibitors", focuses on the design and ...
- Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
CloseCurlyDoubleQuote; The presentation, titled “Targeting Biological Synergy At the Receptor Level – Multi-specific Cytokine Inhibitors”, focuses on the design and development ...
- Equillium Announces Presentation at the 3rd Annual Cytokine-Based Drug Development Summit
(Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced a ...
- Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the ...
- Brooklyn Immunotherapeutics Announces Results Of Phase 2 Study Of IRX-2 In Head And Neck Cancer
Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the“Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with ...